We use large-scale, unbiased screening strategies, allowing for disease to instruct us on the best therapeutic targets. The outcome of these leading-edge approaches is the identification of therapeutic targets that are directly relevant to our diseases of interest.
We utilize optimized immunization strategies, including DNA-based methods, to significantly enhance the probability of creating antibodies that are selective to targets in their native conformations. This markedly increases our success rates in developing assets that are functionally relevant and, consequently, have marked therapeutic potential.
Unlike traditional companies, our medications do not target diseased cells and tissues (e.g., cancer cells and tumors), but are rather designed to harness the power of the immune system to combat disease. Immune cells have a dynamic and far superior capacity to combat disease relative to any static medication-targeting disease. Thus, our therapies engage healthy cells instead of targeting diseased ones.
.jpg)
mAbs are laboratory-produced molecules designed to bind specifically to certain antigens, usually on the surface of cells, like tumor cells. These antibodies can enhance the immune system’s ability to attack these cells or block pathways that cancer cells use to grow. They are extensively used in oncology.
.jpg)
ADCs are composed of a monoclonal antibody linked to a cytotoxic (cell-killing) drug. The antibody directs the drug to target-specific cells (like cancer cells), and the drug is released to kill the cell. This allows for highly targeted delivery of chemotherapy agents, limiting damage to healthy cells. ADC technology combines precision targeting with potent chemotherapy.
Bispecifics are engineered antibodies that can bind to two different antigens or epitopes simultaneously. For example, one arm of the antibody might bind to a cancer cell while the other arm binds to a T cell, bringing the two together to initiate direct immune responses against tumors. Bispecific antibodies are an emerging class of immunotherapy, showing promise in cancer treatment due to their dual-targeting capability.
